North China Pharmaceutical Company.Ltd Valuation
Is 600812 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Sales gegen Gleichaltrige
Price-To-Sales gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of 600812 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: 600812 (CN¥4.74) wird unter unserer Schätzung des Fair Value (CN¥7.19) gehandelt.
Deutlich unter dem Marktwert: 600812 unter dem beizulegenden Zeitwert gehandelt wird, jedoch nicht um einen signifikanten Betrag.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 600812?
Other financial metrics that can be useful for relative valuation.
What is 600812's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | CN¥8.22b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.9x |
Enterprise Value/EBITDA | 14.5x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 600812's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 2.5x | ||
688658 Youcare Pharmaceutical Group | 1.8x | 10.0% | CN¥7.4b |
600252 Guangxi Wuzhou Zhongheng GroupLtd | 2.6x | n/a | CN¥8.1b |
002626 Xiamen Kingdomway Group | 3x | n/a | CN¥9.1b |
000989 Jiuzhitang | 2.6x | n/a | CN¥7.6b |
600812 North China Pharmaceutical Company.Ltd | 0.8x | n/a | CN¥8.2b |
Price-To-Sales gegen Gleichaltrige: 600812 ist ein guter Wert, wenn man sein Price-To-Sales Verhältnis (0.8x) mit dem Durchschnitt der anderen Unternehmen (3.7x) vergleicht.
Price to Earnings Ratio vs Industry
How does 600812's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?
Price-To-Sales gegen Industrie: 600812 ist aufgrund seines Price-To-Sales Verhältnisses (0.8x) im Vergleich zum CN Pharmaceuticals Branchendurchschnitt (3.2x) ein guter Wert.
Price to Sales Ratio vs Fair Ratio
What is 600812's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 0.8x |
Fair PS Ratio | n/a |
PM vs. Fair Ratio: Unzureichende Daten zur Berechnung der Price-To-Sales Fair Ratio von 600812 für die Bewertungsanalyse.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analysten-Prognose: Unzureichende Daten für eine Preisprognose.